Navigation Links
Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
Date:12/20/2007

/p>

In recent months, Peregrine has implemented a number of initiatives to accelerate its three lead clinical programs.

Bavituximab Solid Tumor Clinical Program

In support of the Phase II bavituximab cancer program, Peregrine filed protocols for two breast cancer combination therapy trials and has already received regulatory approval to proceed with one of those protocols, which is assessing bavituximab in combination with docetaxel in patients with breast cancer. Patient enrollment in this trial is expected to begin in early 2008. Regulatory approval for the second breast cancer trial and for a previously filed combination therapy trial in patients with non-small cell lung cancer is expected early in 2008. The company also is taking action to accelerate its Phase I bavituximab cancer trial in the U.S., with the goal of laying the foundation for U.S. Phase II studies. Peregrine recently added a new study site in Charlotte, North Carolina, and a total of five clinical sites are now screening and recruiting patients for this study. Peregrine expects to complete the Phase I trial during 2008. The bavituximab cancer clinical program will be discussed at an important scientific forum when interim clinical data is presented in February 2008 at the 10th Annual International Symposium on Anti-Angiogenic Agents (Angio 2008).

Bavituximab Hepatitis C Virus (HCV) Clinical Program

The company's trial of bavituximab in HCV patients co-infected with HIV began enrolling and dosing patients, and with the addition of new clinical sites at The Johns Hopkins Hospital and a private clinic in Orange County, California, a total of three clinical sites are now screening and recruiting patients in this innovative study. The bavituximab HCV clinical program was awarded an oral presentation slot for the second year in a row at the prestigious Annual Meeting of the American Association for the Study of Liver Disease held last November. Final results from the Phase
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 The College of New Rochelle ... in the Mid-Hudson Region to be designated as a ... applications from qualified “high-technology” businesses that align with the ... to have been selected for the START-UP NY program ... to stimulate economic development in New York by growing ...
(Date:8/21/2014)... 2014  Four-dimensional (4-D) printing develops materials that ... stimuli such as changes in temperature. This advanced ... in multiple industries.  In the near future, 4-D ... objects ranging from human organs to parts used ... Logo - http://photos.prnewswire.com/prnh/20140820/138289 ...
(Date:8/21/2014)... On Wednesday of last week RENU 28, the world's ... became available for purchase in Australia and New Zealand, and ... 28 works is, if you think about the definition of ... cellular renewal within your body. If you think about the ... cellular renewal. What RENU 28 does is it works with ...
(Date:8/20/2014)... Neurotrope, Inc. (OTCQB: NTRP) today announced ... provide an update on Company activities. Access information:Date:Tuesday, ... 505-4369 (U.S. and Canada) or (719) 325-2315 Conference ... under "Investor Relations"The teleconference replay will be available ... 2014 at (888) 203-1112 (U.S. and ...
Breaking Biology Technology:The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 4RENU 28 Skin Care Now Available in Australia and New Zealand 2Neurotrope To Host Conference Call 2
... program draws on diverse group to advise on complex infertility ... ... Science,Center of the Bay Area (RSC) is launching an innovative advisory group,designed ... rare development in private medical groups in the,United States. RSC,s ethics ...
... ISELIN, N.J., Nov. 7 SyntheMed, Inc. (OTC,Bulletin ... development,and commercialization of anti-adhesion, tissue repair and drug ... universal shelf registration,statement with the Securities and Exchange ... will allow SyntheMed to sell, from time to,time, ...
... Nov. 7 Transgenomic Inc. (OTC,Bulletin Board: TBIO) announces the following Webcast: ... Conference Call, ... Where: http://www.transgenomic.com/events.asp?id=6 , How: ... at the ...
Cached Biology Technology:California IVF Experts Tap Ethics Committee for Guidance 2SyntheMed Files Universal Shelf Registration 2Webcast Alert: Transgenomic Inc. Announces Third Quarter 2007 Earnings Release Conference Call Webcast 2
(Date:8/20/2014)... persist in a cold, dark world. A UT microbiology ... waters and sediments from a shallow lake deep beneath ... supports microbial ecosystems. , The National Science Foundation-funded ... for life in other extreme environments, both on Earth ... in the current edition of the science journal ...
(Date:8/20/2014)... this image of the Para and Mato Grosso states ... intentionally set in order to deforest the land. Deforestation ... trees where the land is thereafter converted to a ... to farms, ranches, or urban use. The herringbone-patterned tan ... Rainforest in the middle of the image are evidence ...
(Date:8/20/2014)... Institutes of Health has awarded the Oklahoma Medical Research ... research on anthrax and the bacteria,s effects on humans. ... Ph.D., and his colleagues have studied the human immune ... Centers for Human Immunology. The original funding came soon ... the heels of the terrorist attacks of Sept. 11, ...
Breaking Biology News(10 mins):University of Tennessee research uncovers subglacial life beneath Antarctic ice sheet 2$14.5 million grant awarded to continue anthrax studies 2
... Singapore, September 3, 2010 Novartis announced today ... (NITD), in collaboration with researchers from the Genomics Institute ... and Public Health Institute and The Scripps Research Institute ... a next generation treatment for drug resistant malaria. Major ...
... the extreme Texas summer heat? Try being an ovulating ... dairy cows suffer from damage to their ovarian follicles. ... also be damaged, said Dr. Todd Bilby, Texas AgriLife ... other studies have shown the eggs she ovulates for ...
... pharmaceutical breakthroughs require 21st-century drug discovery tools, such ... high-throughput screening of effective, new compounds. That,s the ... be held Sept. 11 on "Twenty-first Century Bioscience: ... feature a variety of cutting-edge advances in the ...
Cached Biology News:Novartis and collaborators discover novel antimalarial drug candidate 2Novartis and collaborators discover novel antimalarial drug candidate 3Test-tube calf embryos more likely to survive Texas summers 2Test-tube calf embryos more likely to survive Texas summers 3University at Buffalo symposium on in silico methods, high throughput screening 2University at Buffalo symposium on in silico methods, high throughput screening 3
Syd-2 (cL-19)...
... for isolation and affinity purification of ... peptides. Hydrophobic, monodisperse magnetic particles (2.8 ... groups, further surface activation is not ... with optimal orientation for affinity purification ...
ZO-2 (H-110)...
p-Bcl-2 (Thr 74)...
Biology Products: